Glaukos works relentlessly to create and deliver transformative therapies for patients struggling with glaucoma, corneal disorders, and retinal diseases.

At Glaukos, we’ll go first – we won’t play it safe. We strive. We reach. We dream big and deliver even bigger. We think harder, listen better, and innovate faster because each and every Glaukos employee dares to BE more. Dream More and imagine the impossible. Lead more and inspire the success of others. Care More by putting empathy into ...

Founded in 1998, Glaukos is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Feb 24, 2025 · Glaukos Corporation One Glaukos Way Aliso Viejo, CA 92656. 949-481-0510 Send Email Fax: 949-367-9984

Find the latest Glaukos Corporation (GKOS) stock quote, history, news and other vital information to help you with your stock trading and investing.

Dec 14, 2023 · Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment …

Dec 14, 2023 · Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal...

Jan 6, 2022 · Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME ™ Viscodelivery System, a sterile ...

Dec 19, 2024 · Glaukos is a worldwide pharmaceutical and medical technology leader in ophthalmology focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

iDose TR Phase 3 Clinical Trials, data on file, Glaukos Corporation. iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.